Published in final edited form as:

J Community Health. 2019 June ; 44(3): 561–568. doi:10.1007/s10900-019-00646-5.

Aspirin use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs

Jeremy R. Van't Hof, MD¹ [Cardiovascular Medicine Fellow], Sue Duval, PhD¹ [Associate Professor], Jeffrey R. Misialek, MPH^{1,2} [Research Fellow], Niki C. Oldenburg, DrPH¹ [CVD Prevention and Evaluation Scientist], Clarence Jones, MEd³ [Co-founder], Milton Eder, PhD⁴ [Assistant Professor], and Russell V. Luepker, MD, MS² [Mayo Professor]

¹Cardiovascular Division, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN, USA, 55455

²Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 S. Second St. Ste. 300, Minneapolis, MN, USA, 55454

³Hue-Man Partnership, 4243 4th Ave S., Minneapolis, MN, USA, 55409

⁴Department of Family Medicine and Community Health, University of Minnesota Medical School, 717 Delaware Street SE, Minneapolis, MN, USA, 55414

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States, disproportionately affecting African Americans. Aspirin is an effective, low cost option to reduce cardiovascular events. This study sought to describe the use of aspirin for CVD prevention in African Americans and evaluate associations with demographics, cardiovascular risk factors and health behaviors and beliefs. A total of 684 African Americans adults ages 45-79 years completed surveys and were included in this analysis. Proportions of aspirin use were stratified by primary and secondary prevention and by number of CVD risk factors in the primary prevention population. Logistic regression was used to evaluate associations with aspirin use. Secondary prevention aspirin use was 62%. Primary prevention aspirin use was 32% overall and increased to 54% in those with >2 CVD risk factors. A history of diabetes (adjusted odds ratio [aOR] 3.42, 95% CI 2.18-5.35) and hypertension (aOR 2.25, 95% CI 1.39-3.65) were strongly associated with primary prevention aspirin use, but a conversation with a health care provider was even stronger (aOR 6.41, 95% CI 4.07-10.08). Participants who answered positively to statements about people similar to them taking aspirin or that close contacts think they should take aspirin, were much more likely to take aspirin (aOR 4.80; 95% CI 2.58-8.93 and aOR 7.45; 95% CI 4.70-11.79 respectively). These findings support a hypothesis that aspirin use may increase by encouraging conversations with health care providers and creating a supportive social environment for aspirin use. Further studies need to be done to test this hypothesis.

Correspondence: Jeremy R. Van't Hof, Cardiovascular Division, University of Minnesota Medical School, MMC 508, 420 Delaware Street SE, Minneapolis, MN, USA 55455, Tel: 507-227-4445, vanth008@umn.edu.

Conflict of Interest: The authors declare that they have no conflict of interest.

Keywords

aspirin; prevention; cardiovascular disease; African Americans; health behavior

BACKGROUND

Cardiovascular disease (CVD) is the leading cause of disability and death in the United States [1]. African Americans are disproportionately affected by CVD with a higher incidence of disease and increased mortality compared to Whites [1, 2]. While substantial progress has been made to reduce mortality from heart disease and stroke, improvement has begun to plateau. The annual rate of decline in mortality for Non-Hispanic Blacks has slowed from 3.71% in 2000-2011 to 1.29% in 2011-2014 [3]. There remains considerable opportunity to address disparities in cardiovascular outcomes. The most effective approach is to prevent the onset and progression of disease. One prevention strategy that has been used for years is low dose aspirin.

The benefits of aspirin after a heart attack or stroke are well proven [4, 5], and aspirin use for secondary prevention has increased over time in the general public [6]. Several well-designed clinical trials have demonstrated a reduction in a first myocardial infarction (MI) or stroke in participants taking low dose aspirin, at the expense of increased bleeding events [7–13]. This evidence has led multiple organizations to publish recommendations on primary and secondary prevention aspirin use. In 2009, the United States Preventive Services Task Force (USPSTF) published aspirin recommendations based on age and risk level. A positive recommendation was made for women ages 55-79 and for men ages 45-79 with elevated risk for CVD and a risk reduction benefit that outweighed bleeding risk [14]. These recommendations were updated in 2016 after completion of this study.

There is evidence of suboptimal primary prevention aspirin use in moderate to high risk individuals [15]. Contemporary preventive aspirin use rates among African Americans are limited but historically have been lower than aspirin use in Whites for both primary and secondary prevention [16–21]. Guidelines for aspirin do little to influence use [15], likely related in part to the difficulty in changing both provider and patient patterns of behavior. Behavior change techniques are an area of interest not only for treatment adherence but for many healthy lifestyle adjustments [22]. Beliefs about health behavior—such as self-efficacy, intention to modify a behavior, perceived social norms—have been associated with prevalence and control of CVD risk factors, and interventions targeting behavior change can be effective in improving smoking cessation, physical activity, blood pressure control and medication adherence [22–25]. However, there is little information regarding the effect of health behavior beliefs on aspirin use in an African American population at risk for a cardiovascular event.

The present study was designed to describe contemporary aspirin use for CVD prevention in African American adults, and to evaluate associations of use with demographics, socioeconomic status, CVD risk factors and health behavior beliefs.

METHODS

Population and Setting

This study was conducted between April and August 2015 within the Minneapolis-Saint Paul metropolitan area. We recruited men ages 45-79 years and women 55-79 years by collaborating with community health workers with previous experience working in communities of color. Recruitment sites included churches, gyms, public events (community and health fairs), senior housing and community centers. A total of 784 individuals were enrolled. For this study, we only included individuals who self-identified as Black or African American and had complete information for sex and CVD risk factors (diabetes mellitus, current smoking, hypertension and hyperlipidemia). Participants were excluded if their main residence was outside of Minnesota. This resulted in a total of 684 surveys included in the final analysis (74 excluded for race; 22 excluded for missing data; 4 excluded for residence). All participants were offered a \$10 gift card to participate. The requirement for written informed consent was waived by the University of Minnesota IRB due to the minimal risk of the study.

Data Collection

A 10-minute, in-person survey was administered by trained community health workers. Survey questions addressed demographics and self-reported history of CVD to identify primary and secondary prevention populations as well as risk factors for CVD. CVD risk factors included diabetes mellitus, current smoking, hypertension and hyperlipidemia. Positive CVD history was defined as a history of heart attack, stroke or peripheral artery disease; or history of an endovascular or surgical procedure to revascularize coronary, carotid or limb arteries. Individuals with no history of CVD or revascularization procedures were considered the primary prevention sample. The survey examined aspirin use, other antithrombotic medication use, CVD risk perceptions, past aspirin-related discussions with a health care provider and health behavior beliefs and social norms related to aspirin use. Positive aspirin use was defined as daily or every other day use of low dose aspirin. Other antithrombotic medications specified in the survey included warfarin and clopidogrel. Nine questions related to health behavior beliefs and social norms were formulated based on the theory of planned behavior [26], which has been used in prior studies to evaluate health behaviors related to CVD [23, 24]. The questions are displayed in Supplemental Table 1.

Statistical Analysis

Descriptive data were stratified by primary and secondary prevention populations. Within the primary prevention sample, individuals were further stratified by number of risk factors. Categorical data are reported as n (%) and continuous data as mean [(standard deviation (SD))].

For primary prevention individuals, logistic regression was used to examine the association of aspirin use with demographics and cardiovascular risk factors. Adjustments were made for age, sex and CVD risk factors. Health behavior beliefs including CVD risk perceptions and aspirin-related health beliefs and social norms were evaluated using a 4-point Likert scale (strongly disagree, disagree, agree and strongly agree). If agree or strongly agree was

chosen, this was considered a positive response to the question. Logistic regression was used to evaluate the association of aspirin use with a positive response to individual questions and with the number of positive responses modeled as a continuous variable. Interaction testing was done for prevention status and number of positive responses. This was non-significant, so primary and secondary prevention individuals were combined in the analysis of health behavior beliefs. We included an unadjusted model, a model with adjustment for age, sex and prevention status and a fully adjusted model that added CVD risk factors. Results are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). All analyses were conducted using Stata version 15 (Stata Corp, College Station, Texas, USA).

The study was reviewed and approved by the University of Minnesota Institutional Review Board.

RESULTS

Participant characteristics are described in Table 1. The mean age was 61.4 years with an older female population (64.2 ± 6.5 years) compared to males (58.4 ± 8.0 years). Fifty-two percent of participants were female, and 1% identified as Hispanic. Over 30% achieved a minimum of a college degree. CVD risk factors were common in this sample and higher in the secondary prevention population. Nearly all participants identified a primary care provider (94%), which was a similar finding in primary and secondary prevention populations. Over 60% exhibited past prevention behavior indicated by a recent history of vaccination for influenza. Discussions about aspirin use were more common in the secondary prevention population, as was the use of non-aspirin antithrombotic medications.

Secondary prevention aspirin use was 62% overall while 75% of participants used either aspirin or another form of antithrombotic medication. Total primary prevention aspirin use was lower (32%) and varied by age and number of risk factors (Figure 1). Primary prevention aspirin use increased as the number of CVD risk factors increased (p for trend <0.0001) regardless of age (p for interaction $=0.73$). Of participants with 0-1 risk factor, 21% were taking aspirin. In contrast, 54% of those with >2 risk factors were taking the medication (Figure 1).

There were several factors associated with primary prevention aspirin use (Table 2). When modeled as a continuous variable, age was associated with a 7% increase per year after multivariable adjustment (aOR 1.07, 95% CI 1.03-1.10). Sex and level of education were not significantly associated with aspirin use. In the unadjusted analysis, participants with a history of diabetes, hypertension or hyperlipidemia were more likely to use aspirin, but smokers were less likely. However, after adjustment for age, sex and CVD risk factors, only a history of diabetes (aOR 3.42, 95% CI 2.18-5.35) and hypertension (aOR 2.25, 95% CI 1.39-3.65) remained associated with aspirin use. The strongest predictor was a history of a conversation about aspirin with a healthcare provider (aOR 6.41, 95% CI 4.07-10.08).

After adjustment for age, sex, CVD risk factors and prevention status (primary vs secondary), several health behavior beliefs were associated with increased aspirin use (Figure 2). Participants were more likely to take aspirin if they answered positively

compared with those who responded negatively to statements regarding trust in their doctor (aOR 1.85, 95% CI 1.03-3.31); higher risk of future heart attack or stroke (aOR 1.51, 95% CI 1.05-2.17); safety of aspirin (aOR 26.89, 95% CI 11.69-61.87); and ease of aspirin use (aOR 20.89, 95% CI 9.02-48.38). As well, aspirin use was more likely when perceived positively in a social context. Participants who answered positively to the statement that people similar to them take aspirin were 4.80 times more likely to take aspirin (95% CI 2.58-8.93). When close contacts thought they should be taking aspirin, respondents were 7.45 times more likely to take the medication than those who responded to the question negatively (95% CI 4.70-11.79). In the fully adjusted model, the likelihood of aspirin use doubled with each positive response when the total number of positive responses were modeled as a continuous variable (aOR 2.12, 95% CI 1.83-2.45, $p < 0.0001$).

DISCUSSION

This study provides data on primary and secondary prevention aspirin use in a contemporary, urban sample of African American adults and may help identify opportunities to improve appropriate aspirin use. It highlights the positive association between aspirin use, recognized CVD risk factors and conversations with primary care providers about medication use. Multiple health behavior beliefs were also associated with aspirin use including statements related to social context and social norms.

Prevalence of Preventive Aspirin Use

This study demonstrates a prevalence of secondary prevention aspirin similar to that reported in other African American and multi-racial populations [20, 21, 27, 28], but aspirin use in African Americans has historically been lower than use in Whites. For example, Gu et al. reported a 68% prevalence of secondary prevention aspirin use among Non-Hispanic Blacks vs 77% for Non-Hispanic Whites using data from the 2011-2012 National Health and Nutrition Survey (NHANES) [28]. However, aspirin use among African Americans has increased over time. In 1987-1989, Atherosclerosis Risk in Communities (ARIC) Study investigators found aspirin use in Black men and women after a heart attack was 49% and 23% respectively [16]. Epidemiologic data from Minnesota shows a steady increase in secondary prevention aspirin use over 25 years [6].

Primary prevention aspirin use appropriately increased as CVD risk increased in this sample — 54% percent of participants with 3-4 risk factors were taking aspirin compared to 21% with 0-1 risk factors—but moderate to high risk individuals may still be undertreated. This study did not have the information required to calculate a 10-year CVD risk score, but many participants with 2 or more risk factors likely fall above the age-specific, 8-12% risk thresholds designated in the 2009 USPSTF recommendations [14]. Many African American men and women with 2-3 risk factors will reach a 10% 10-year CVD risk threshold between the ages of 50-60 years [29]. The overall prevalence of primary prevention aspirin use of 32% in this study is similar to other African American populations. Using data from the 2005-2007 Multi-Ethnic Study of Atherosclerosis (MESA), Sanchez et al reported primary prevention aspirin prevalence of 19%, 27% and 43% in Blacks with low (<6%), increased (6-9.9%) and high (≥ 10%) risk respectively, based on Framingham risk score. This was

significantly less than aspirin use reported in Whites with 29%, 41% and 53% prevalence at low, increased and high risk respectively [19]. In the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study, primary prevention aspirin use was lower than we observed among African Americans (27.2%), although these data are over 10 years old [18].

Associations with Primary Prevention Aspirin Use

In unadjusted analysis, all CVD risk factors were associated with increased aspirin use except for smoking. After adjustment for age, sex and CVD risk factors, only hypertension and diabetes remained positively associated with aspirin use. This contrasts with the REGARDS study [18] and a large clinical sample [15] where all risk factors remained significantly associated with aspirin use after similar adjustment. This may be due to the smaller sample size in the current study. The strong association found in diabetics likely reflects the impact of the American Diabetes Association recommendations. This sample was highly educated, but as shown in previous studies [17–19], education was not independently associated with aspirin use.

The participants in this study exhibited a high level of engagement with the health care system. Over 90% identified a regular health care provider, and two thirds received an influenza vaccination in the past 2 years. The most powerful clinical predictor of aspirin use was a conversation with a health care provider (aOR 6.41, Table 2). This strong association was also reported by Williams et al. in a survey of U.S. adults ages 45–79, where a conversation with a medical provider was the strongest predictor (OR 23.8, 95% CI 17.7–31.5) [30]. Despite a history of mistrust between African Americans and physicians [31], these results suggest discussions regarding preventive therapies may be effective.

Beliefs About Health and Behavior

The questions about health behavior beliefs were formulated based on the theory of planned behavior, which was developed by Ajzen [26]. The theory is based on three components. The first is attitude towards a behavior, whether or not a person views the behavior favorably. The second is subjective norm. This is the perceived social acceptance or pressure to perform a certain behavior. The final component is perceived behavior control referring to the ease or difficulty of performing a behavior. Our study demonstrated strong associations between aspirin use and positive social norms/attitudes about aspirin use. There was also a strong, positive association with ease and safety of aspirin use. This theory has been used to explain aspirin use in women with high risk pregnancy [25] but not, to our knowledge, for general CVD prevention. It has been used to describe other CVD prevention behaviors including physical activity [23] and smoking cessation [24].

This study adds support to other studies that seek to shift patient-focused medical education and therapy in African Americans from the clinic to the community. A recently published trial evaluating a pharmacist driven blood pressure intervention in barber shops showed a significant reduction in blood pressure in the intervention arm [32]. The average reduction in systolic blood pressure was 21.6 mmHg greater in the intervention group. Part of the success of this program that targeted African American men was the ability to incorporate peer support. Our study suggests this concept may be applicable to aspirin use as well. There was

a strong association between aspirin use and those who believed that people similar to them were using aspirin or people close to them thought they should be using aspirin. Education to increase knowledge about the safety and effectiveness of aspirin may also increase aspirin use. Additional studies could be done to test the effectiveness of an intervention to increase community awareness around aspirin use or other community-based efforts to increase aspirin use.

Limitations

This study has several limitations. This was a convenience sample limited to a single state and may not be widely generalizable. Participants were screened at community-based locations and may exclude those who are less involved or active in the community. Many of the screening locations were health focused (gyms, health fairs). People found at these sites are likely to be more interested in their health than the general public, although the prevalence of CVD risk factors in this sample was still high. Medical history and medication use were obtained by selfreport and could not be adjudicated. However, there is evidence supporting the accuracy of self-reported aspirin use [33]. These results should be considered as hypothesis generating data that may inform additional, more rigorous evaluations.

CONCLUSION

This study examined aspirin use for CVD prevention among a contemporary, urban, African American population. Increased CVD risk, an aspirin-related conversation with a health provider and beliefs about peer attitudes regarding aspirin use were associated with increased aspirin use. Further studies should be done to evaluate the effect of changing individual and community beliefs regarding aspirin use for CVD prevention.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This study was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, R01HL126041

This project was supported in part by a grant from the National Heart, Lung, and Blood Institute, National Institutes of Health, R01HL126041

References

1. Benjamin EJ, Virani SS Callaway CW, et al. (2018). Heart disease and stroke statistics-2018 update: A report from the American Heart Association. *Circulation*, 137(12), e67–e492. [PubMed: 29386200]
2. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, & Croft JB (2005). State of disparities in cardiovascular health in the United States. *Circulation*, 111(10), 1233–1241. [PubMed: 15769763]
3. Sidney S, Quesenberry CP, Jaffe MG, et al. (2016). Recent trends in cardiovascular mortality in the United States and public health goals. *JAMA Cardiology*, 1(5), 594–599. [PubMed: 27438477]
4. Baigent C, Blackwell L, Collins R, et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*, 373(9678), 1849–1860. [PubMed: 19482214]

5. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, & Mehta Z (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. *Lancet*, 388(10042), 365–375. [PubMed: 27209146]
6. Luepker RV, Steffen LM, Duval S, Zantek ND, Zhou X, & Hirsch AT (2015). Population trends in aspirin use for cardiovascular disease prevention 1980–2009: the Minnesota Heart Survey. *Journal of the American Heart Association*, 4(12), e002320. [PubMed: 26702085]
7. Steering Committee of the Physicians' Health Study Research Group*. (1989). Final report on the aspirin component of the ongoing Physicians' Health Study. *New England Journal of Medicine*, 321(3), 129–135. [PubMed: 2664509]
8. Hansson L, Zanchetti A, Carruthers SG, et al. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet*, 351(9118), 1755–1762. [PubMed: 9635947]
9. Medical Research Council's General Practice Research Framework. (1998). Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet*, 351(9098), 233–241. [PubMed: 9457092]
10. Ridker PM, Cook NR, Lee IM, et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *New England Journal of Medicine*, 352(13), 1293–1304. [PubMed: 15753114]
11. Ikeda Y, Shimada K, Teramoto T, et al. (2014). Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. *JAMA*, 312(23), 2510–2520. [PubMed: 25401325]
12. ASCEND Study Collaborative Group. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. *New England Journal of Medicine*, 379(16), 1529–1539. [PubMed: 30146931]
13. Gaziano JM, Brotons C, Coppolecchia R, et al. (2018). Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. *Lancet*, 392(10152), 1036–1046. [PubMed: 30158069]
14. Calonge N, Petitti DB, DeWitt TG, et al. (2009). Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. *Annals of Internal Medicine*, 150(6), 396–404. [PubMed: 19293072]
15. Van't Hof JR, Duval S, Walts A, Kopecky SL, Luepker RV, & Hirsch AT (2017). Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007-2015: A Serial, Cross-sectional Study. *Journal of the American Heart Association*, 6(10), e006328. [PubMed: 28974502]
16. Shahar E, Folsom AR, Romm FJ, et al. (1996). Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. *American Heart Journal*, 131(5), 915–922. [PubMed: 8615310]
17. Rodondi N, Vittinghoff E, Cornuz J, et al. (2005). Aspirin use for the primary prevention of coronary heart disease in older adults. *The American Journal of Medicine*, 118(11), 1288–e1.
18. Glasser SP, Cushman M, Prineas R, et al. (2008). Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? *Preventive Medicine*, 47(2), 161–166. [PubMed: 18597839]
19. Sanchez DR, Roux AVD, Michos ED, Blumenthal RS, Schreiner PJ, Burke GL, & Watson K (2011). Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. *The American Journal of Cardiology*, 107(1), 41–46. [PubMed: 21146684]
20. Johansen ME, Hefner JL, & Foraker RE (2015). Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. *The American Journal of Cardiology*, 115(11), 1507–1512. [PubMed: 25840577]
21. Fang J, George MG, Gindi RM, et al. (2015). Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). *The American Journal of Cardiology*, 115(7), 895–900. [PubMed: 25670639]

22. Winter SJ, Sheats JL, & King AC (2016). The use of behavior change techniques and theory in technologies for cardiovascular disease prevention and treatment in adults: a comprehensive review. *Progress in Cardiovascular Diseases*, 58(6), 605–612. [PubMed: 26902519]
23. Plotnikoff RC, Lubans DR, Costigan SA, & McCargar L (2013). A test of the theory of planned behavior to predict physical activity in an overweight/obese population sample of adolescents from Alberta, Canada. *Health Education & Behavior*, 40(4), 415–425. [PubMed: 22984208]
24. Norman P, Conner M, & Bell R (1999). The theory of planned behavior and smoking cessation. *Health Psychology*, 18(1), 89–94. [PubMed: 9925050]
25. Lin CY, Broström A, Nilsen P, & Pakpour AH (2018). Using extended theory of planned behavior to understand aspirin adherence in pregnant women. *Pregnancy Hypertension*, 12, 84–89. [PubMed: 29674206]
26. Ajzen I (1991). The theory of planned behavior. *Organizational Behavior and Human Decision Processes*, 50(2), 179–211.
27. Brown DW, Shepard D, Giles WH, Greenlund KJ, & Croft JB (2005). Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. *Ethnicity & Disease*, 15(4), 620–626. [PubMed: 16259485]
28. Gu Q, Dillon CF, Eberhardt MS, Wright JD, & Burt VL (2015). Preventive aspirin and other antiplatelet medication use among US adults aged 40 years: data from the National Health and Nutrition Examination Survey, 2011–2012. *Public Health Reports*, 130(6), 643–654. [PubMed: 26556936]
29. Karmali KN, Goff DC, Ning H, & Lloyd-Jones DM (2014). A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. *Journal of the American College of Cardiology*, 64(10), 959–968. [PubMed: 25190228]
30. Williams CD, Chan AT, Elman MR, et al. (2015). Aspirin use among adults in the US: results of a national survey. *American Journal of Preventive Medicine*, 48(5), 501–508. [PubMed: 25891049]
31. Halbert CH, Armstrong K, Gandy OH, & Shaker L (2006). Racial differences in trust in health care providers. *Archives of Internal Medicine*, 166(8), 896–901. [PubMed: 16636216]
32. Victor RG, Lynch K, Li N, et al. (2018). A cluster-randomized trial of blood-pressure reduction in black barbershops. *New England Journal of Medicine*, 378(14), 1291–1301. [PubMed: 29527973]
33. Zantek ND, Luepker RV, Duval S, Miller K, Oldenburg N, & Hirsch AT (2014). Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. *Clinical and Applied Thrombosis/Hemostasis*, 20(4), 385–392. [PubMed: 23653145]

Figure 1: Primary prevention aspirin use by age and number of cardiovascular disease risk factors.

Primary prevention aspirin use increased as the number of cardiovascular risk factors (current smoker, diabetes mellitus, hyperlipidemia and hypertension) increased (p for trend <0.0001) regardless of age (p for interaction=0.73).

Figure 2: Association of aspirin use with health behavior beliefs

This figure demonstrates the odds ratios of aspirin use with a positive (strongly agree or agree) or a negative (strongly disagree or disagree) response to each question. Odds ratios were adjusted for age, sex, prevention status (primary vs secondary), current smoking, diabetes mellitus, hyperlipidemia and hypertension. Question 4, regarding the importance of preventing a heart attack or stroke, was removed as only three participants responded no, and none of them used aspirin.

Table 1:

Participant characteristics by cardiovascular disease (CVD) status and sex

	Total Population		Primary Prevention		Secondary Prevention	
	Women (n=358)	Men (n=326)	Women (n=265)	Men (n=254)	Women (n=93)	Men (n=72)
Age, years	64.2 ± 6.5	58.4 ± 8.0	63.8 ± 6.4	57.5 ± 7.8	65.3 ± 6.5	61.5 ± 7.7
45-49	0 (0)	45 (13.8)	0 (0)	43 (16.9)	0 (0)	2 (2.8)
50-59	103 (28.8)	146 (44.8)	84 (31.7)	114 (44.9)	19 (20.4)	32 (44.4)
60-69	180 (50.3)	102 (31.3)	132 (49.8)	77 (30.3)	48 (51.6)	25 (34.7)
70-79	75 (20.9)	33 (10.1)	49 (18.5)	20 (7.9)	26 (28.0)	13 (18.1)
Ethnicity						
Hispanic	1 (0.3)	9 (2.8)	1 (0.4)	7 (2.8)	0 (0)	2 (2.8)
Non-Hispanic	355 (99.2)	314 (96.3)	262 (98.9)	245 (96.5)	93 (100)	69 (95.8)
Education						
<High school graduate	45 (12.6)	51 (15.6)	29 (10.9)	33 (13.0)	16 (17.2)	18 (25.0)
High school graduate	96 (26.8)	102 (31.3)	75 (28.3)	84 (33.1)	21 (22.6)	18 (25.0)
Some college	90 (25.1)	77 (23.6)	63 (23.8)	56 (22.1)	27 (29.0)	21 (29.2)
College degree/graduate school	125 (34.9)	94 (28.8)	97 (36.6)	79 (31.1)	28 (30.1)	15 (20.8)
CVD Risk Factors						
Current smoker	60 (16.8)	129 (39.6)	41 (15.5)	98 (38.6)	19 (20.4)	31 (43.1)
Diabetes	110 (30.7)	93 (28.5)	71 (26.8)	61 (24.0)	39 (41.9)	32 (44.4)
Hyperlipidemia	180 (50.3)	150 (46.0)	124 (46.8)	104 (40.9)	56 (60.2)	46 (63.9)
Hypertension	253 (70.7)	223 (68.4)	181 (68.3)	161 (63.4)	72 (77.4)	62 (86.1)
Other antithrombotic use	36 (10.1)	43 (13.2)	9 (3.4)	19 (7.5)	27 (29.0)	24 (33.3)
Identify a regular health care provider	343 (95.8)	300 (92.0)	252 (95.1)	231 (90.9)	91 (97.9)	69 (95.8)
Received flu vaccine	237 (66.2)	205 (62.9)	170 (64.2)	154 (60.6)	67 (72.0)	51 (70.8)
Discussed aspirin with provider	188 (52.5)	154 (47.2)	122 (46.0)	105 (41.3)	66 (71.0)	49 (68.1)

All values are presented as n (%) except for age which is shown as mean ± standard deviation.

Table 2:

Associations of regular aspirin use with demographics and CVD risk factors in primary prevention individuals (n=519)

	N	Aspirin use n (%)	Unadjusted OR (95% CI)	Multivariable* OR (95% CI)	p-value
Age, years			1.08 (1.05-1.11)	1.07 (1.03-1.10)	<0.0001
45-49	43	9 (21%)	1 (Reference)	1 (Reference)	
50-59	198	38 (19%)	0.90 (0.40-2.03)	0.80 (0.33-1.98)	0.64
60-69	209	84 (40%)	2.54 (1.16-5.57)	1.85 (0.75-4.57)	0.18
70-79	69	37 (54%)	4.37 (1.82-10.47)	2.95 (1.08-8.08)	0.04
Sex					
Women	265	100 (38%)	1.66 (1.14-2.41)	1.07 (0.69-1.67)	0.75
Men	254	68 (27%)	1 (Reference)	1 (Reference)	
Education					
< HS graduate	62	17 (27%)	0.73 (0.39-1.38)	0.72 (0.35-1.49)	0.38
HS graduate	159	58 (36%)	1.11 (0.71-1.74)	1.03 (0.62-1.72)	0.90
Some college	119	33 (28%)	0.74 (0.45-1.23)	0.69 (0.39-1.22)	0.20
College degree	176	60 (34%)	1 (Reference)	1 (Reference)	
Current smoking					
Yes	139	32 (23%)	0.54 (0.34-0.84)	0.78 (0.47-1.29)	0.33
No	380	136 (36%)	1 (Reference)	1 (Reference)	
Diabetes					
Yes	132	75 (57%)	4.16 (2.74-6.30)	3.42 (2.18-5.35)	<0.0001
No	387	93 (24%)	1 (Reference)	1 (Reference)	
Hyperlipidemia					
Yes	228	91 (40%)	1.85 (1.27-2.68)	1.13 (0.74-1.73)	0.58
No	291	77 (26%)	1 (Reference)	1 (Reference)	
Hypertension					
Yes	342	137 (40%)	3.15 (2.02-4.91)	2.25 (1.39-3.65)	0.001
No	177	31 (18%)	1 (Reference)	1 (Reference)	
Identify a regular health care provider					
Yes	483	165 (34%)	7.52 (1.77-31.92)	6.14 (1.35-27.89)	0.02
No	31	2 (6%)	1 (Reference)	1 (Reference)	
Discussed aspirin with a health provider					
Yes	227	126 (56%)	7.43 (4.89-11.29)	6.41 (4.07-10.08)	<0.0001
No	292	42 (14%)	1 (Reference)	1 (Reference)	
Flu shot					
Yes	324	121 (37%)	1.88 (1.26-2.81)	1.43 (0.92-2.23)	0.11
No	191	46 (24%)	1 (Reference)	1 (Reference)	

* Covariates for multivariable logistic regression adjustment: age (as a continuous variable), sex, smoking, diabetes, hyperlipidemia, hypertension

CVD: cardiovascular disease; HS: high school; OR: odds ratio; CI: confidence interval